問卷

TPIDB > Search Result

Search Result

篩選

List

1336Cases

2024-05-03 - 2030-10-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-08-13 - 2030-03-05

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2026-01-01 - 2029-08-31

Phase I/II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2025-12-01 - 2032-08-02

Others

Not yet recruiting
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
  • Condition/Disease

    Primary Biliary Cholangitis

  • Test Drug

    Capsules

Participate Sites
7Sites

Not yet recruiting7Sites

2023-02-15 - 2025-06-30

Phase I

Completed
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)
  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    注射劑 注射劑

Participate Sites
10Sites

Terminated10Sites

2022-09-03 - 2027-08-09

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-03-01 - 2029-04-01

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2025-01-01 - 2031-01-26

Phase III

Active
A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care
  • Condition/Disease

    Virologically suppressed individuals with HIV-1 infection receiving standard therapy.

  • Test Drug

    Islatravir/Lenacapavir

Participate Sites
5Sites

Recruiting5Sites

2024-04-12 - 2028-12-31

Phase II

Active
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    GS-1427

Participate Sites
8Sites

Recruiting8Sites

2017-02-01 - 2024-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites